Elecsys Anti-SARS-CoV-2
Immunoassay for the qualitative detection of antibodies (incl. IgG) against SARS-CoV-2
Fast option to detect during the pandemic.
Human immunization (Ig) by anti-SARS-CoV-2
The product allows the automation of human Ig anti-SARS-CoV-2 detection.
Review Date: 24 Dec 2020
Immunoassay to qualitatively detect antibodies (including IgG) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The assay uses a recombinant protein representing the nucleocapsid (N) antigen in a double-antigen sandwich assay format, which favors detection of high affinity antibodies against SARS-CoV-2. Elecsys® Anti-SARS-CoV-2 detects antibody titers, which have been shown to positively correlate with neutralizing antibodies in neutralization assays. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
The EBV panel can be used to rule out other acute infections, such as missed HIV infections
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission
Roche has announced the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
The SARS-CoV-2 Rapid Antigen Test Nasal uses a nasal swab to quickly and conveniently collect specimens from people suspected of having an active infection
